GoKawiilEli Lilly, Kariya and Baseline advance GLP-1 drugs for brain disorders
Eli Lilly presented early clinical data last month on brenipatide, a tirzepatide-related compound, for alcohol use disorder. Kariya Pharmaceuticals separately reported early results for KP405, a similar GLP-1 compound, in Parkinson's disease, while Baseline Therapeutics said it plans to begin a clinical trial of a GLP-1 compound for alcohol use disorder in early 2027.